Concorde Medicine ApS: Financial statements 2025
CVR: 44411504
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Concorde Medicine ApS (CVR 44411504) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -109,203 and a net result of DKK -81,144. Equity in the 2025 report amounted to DKK -59,586.
- Gross Profit
- DKK -109,203
- Profit/Loss
- DKK -81,144
- Equity
- DKK -59,586
- Total Assets
- DKK 95,414
- Employees
- 0
Official annual report
How creditworthy is Concorde Medicine ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Concorde Medicine ApS has published its interim report for the period November 3, 2023 to December 31, 2024.
On January 7, 2025, the company changed its name from Cullinan Partners ApS to Concorde Medicine ApS.
As of January 6, 2025, Lasse Graugaard has stepped down as director of Concorde Medicine ApS.
About Concorde Medicine ApS
Concorde Medicine ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2023. The company is registered under the industry Anden specialiseret engroshandel i.a.n.. The company was previously named Cullinan Partners ApS. The management consists of Asbjørn Strand Agnholt and Elias Rud Tahi. The company is owned by 365 Sunshine Holding ApS and Concorde Medicine Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -109,203 and a net result of DKK -81,144. Equity in the 2025 report amounted to DKK -59,586.